The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
April 27th 2025, 10:45pm
Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.
April 27th 2025, 10:30pm
American Urological Association Annual Meeting
Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.
April 27th 2025, 8:27pm
Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.
April 27th 2025, 7:45pm
Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.
April 27th 2025, 7:31pm
American Urological Association Annual Meeting
Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.
April 27th 2025, 6:26pm
American Urological Association Annual Meeting
Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.
April 27th 2025, 6:25pm
American Urological Association Annual Meeting
Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.
April 27th 2025, 5:20pm
American Urological Association Annual Meeting
The addition of disitamab vedotin to BCG demonstrated high CR rates in HER2-expressing, high-risk NMIBC.
April 27th 2025, 5:04pm
American Urological Association Annual Meeting
Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.
April 27th 2025, 1:50pm
American Urological Association Annual Meeting
UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.
April 26th 2025, 10:55pm
American Urological Association Annual Meeting
No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.
April 26th 2025, 9:25pm
American Urological Association Annual Meeting
Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.
April 26th 2025, 9:25pm
American Urological Association Annual Meeting
TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.
April 26th 2025, 9:04pm
American Urological Association Annual Meeting
Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.
April 26th 2025, 9:03pm
American Urological Association Annual Meeting
TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.
April 26th 2025, 8:13pm
American Urological Association Annual Meeting
Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.
April 26th 2025, 5:02pm
American Urological Association Annual Meeting
Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.
April 26th 2025, 2:22pm
American Urological Association Annual Meeting
Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.
April 24th 2025, 2:00pm
American Urological Association Annual Meeting
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
April 24th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how the preliminary results from the IMMagine-1 trial (ASH 2024, abstract #1031) on anitocabtagene autoleucel highlight the evolving role of bispecifics and chimeric antigen receptor (CAR) T-cell therapies in the treatment landscape for relapsed/refractory multiple myeloma (R/R MM).